CEL-SCI CORPORATION Finance Lease, Liability, Current
CEL-SCI CORPORATION (CVM) had Finance Lease, Liability, Current of $2.49 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Finance Lease, Liability, Current $2.49M.
- 2026-03-31: Finance Lease, Liability, Current $2.42M.
- 2025-12-31: Finance Lease, Liability, Current $2.34M.
- 2025-09-30: Finance Lease, Liability, Current $2.27M.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $2.49M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $2.42M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.34M 10-Q · filed 2026-02-17 |
| 2025-09-30 | $2.27M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $2.21M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.14M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.07M 10-Q · filed 2025-02-14 |
| 2024-09-30 | $2.01M 10-K · filed 2025-12-29 |
| 2024-06-30 | $1.95M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.89M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.83M 10-Q · filed 2024-02-14 |
| 2023-09-30 | $1.77M 10-K · filed 2025-01-13 |
| 2023-06-30 | $1.72M 10-Q · filed 2023-08-10 |
| 2022-09-30 | $1.56M 10-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |